AstraZeneca Flat as Early Gains Fade Despite New Partnership Boost

As of 11:00 AM on 18 Nov 2025,!

Pharma India traded flat, giving up its initial intraday gains despite announcing a significant expansion in its renal-care portfolio. The company has entered a second brand partnership with Sun Pharmaceutical Industries for Sodium Zirconium Cyclosilicate (SZC), a therapy indicated for managing hyperkalemia in adults. Under the agreement, AstraZeneca will market SZC as Lokelma, while Sun Pharma will distribute it under the name Gimliand. The dual-brand strategy boosts nationwide reach and strengthens therapeutic access, yet the stock reaction remained muted. Investors appear to be awaiting clearer demand visibility before rewarding the partnership with price momentum.